News

VectorY Therapeutics and Shape Therapeutics Inc. have announced a new partnership aimed at advancing gene therapies for neurodegenerative diseases. Under an option and license…
Read More...

Wheeler Bio, a U.S.-based contract development and biomanufacturing organization (CDMO), has signed a partnership agreement with MindImmune Therapeutics to support the development of…
Read More...

The New England Journal of Medicine has published the results from Novo Nordisk’s OASIS 4 Phase 3 trial, marking a major advance in obesity treatment with the investigational once-daily…
Read More...

GSK plc announced plans to invest $30 billion in the United States over the next five years, focusing on research and development and supply chain infrastructure. This major investment…
Read More...

Mabwell (Shanghai) Bioscience Co., Ltd. and Aditum Bio have announced the formation of a new biotech company, Kalexo Bio, focused on developing RNA-based therapies for cardiovascular…
Read More...

Adagene Inc. has announced an amendment to its 2021 collaboration and license agreement with Exelixis, allowing Exelixis to use Adagene’s SAFEbody technology to create a third masked…
Read More...

Reunion Neuroscience, a clinical-stage biopharmaceutical company focused on next-generation psychedelic-inspired therapies for mental health, announced the final closing of its Series A…
Read More...

VarmX, a biotech company specializing in treatments for patients on direct oral anticoagulants targeting activated factor Xa (FXa DOACs), has entered a strategic collaboration with…
Read More...

Raludotatug deruxtecan (R-DXd), a novel CDH6-targeted antibody-drug conjugate developed by Daiichi Sankyo and Merck, has received Breakthrough Therapy Designation (BTD) from the U.S.…
Read More...

Akeso Inc. announced that its monoclonal antibody ligufalimab (AK117), targeting CD47, has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration for the…
Read More...

Cadrenal Therapeutics, Inc., a biopharmaceutical company focused on innovative anticoagulation therapies, has announced the acquisition of eXIthera Pharmaceuticals’ portfolio of Factor…
Read More...

aTyr Pharma, Inc. a clinical-stage biotech company developing first-in-class therapeutics from its proprietary tRNA synthetase platform, today announced topline results from its Phase 3…
Read More...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has approved an update to the label of Novo Nordisk’s oral diabetes drug Rybelsus (oral…
Read More...

Amneal Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA) for sodium oxybate oral solution 500 mg/mL, a…
Read More...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to Sanofi’s investigational gene therapy SAR402663 for treating neovascular age-related macular…
Read More...

Charles River Laboratories International, Inc. has announced two strategic partnerships aimed at advancing oncology research and accelerating the development of novel cancer therapies.…
Read More...

Zentiva, a leading European generics pharmaceutical company, has been sold by Advent International to GTCR, two major global private equity firms announced today. Advent acquired…
Read More...

The Chinese National Medical Products Administration (NMPA) has approved Tzield (teplizumab) as the country’s first disease-modifying therapy for autoimmune type 1 diabetes (T1D). The…
Read More...

Kriya Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering gene therapies for chronic diseases, has announced the closing of a $320 million Series D financing. The…
Read More...

Merck, known as MSD outside the U.S. and Canada, announced positive results from its Phase 3 STRIDE-13 trial evaluating CAPVAXIVE, its 21-valent pneumococcal conjugate vaccine, in…
Read More...